Avenue Therapeutics Inc (NASDAQ:ATXI) was the target of a large decline in short interest during the month of June. As of June 30th, there was short interest totalling 44,100 shares, a decline of 16.3% from the May 30th total of 52,700 shares. Based on an average daily volume of 61,700 shares, the short-interest ratio is presently 0.7 days. Approximately 0.7% of the shares of the company are short sold.

NASDAQ ATXI opened at $6.24 on Friday. Avenue Therapeutics has a twelve month low of $2.08 and a twelve month high of $7.98. The business’s 50-day simple moving average is $5.86.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.39). Analysts forecast that Avenue Therapeutics will post -1.82 earnings per share for the current fiscal year.

In other Avenue Therapeutics news, Director Neil Herskowitz acquired 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The stock was acquired at an average price of $5.86 per share, with a total value of $29,300.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.00% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. Northern Trust Corp acquired a new position in Avenue Therapeutics in the 4th quarter valued at approximately $79,000. Spark Investment Management LLC acquired a new position in Avenue Therapeutics in the 1st quarter valued at approximately $144,000. Finally, Opaleye Management Inc. acquired a new position in Avenue Therapeutics in the 4th quarter valued at approximately $2,678,000. 7.01% of the stock is owned by hedge funds and other institutional investors.

Several research firms recently weighed in on ATXI. HC Wainwright set a $25.00 price objective on Onconova Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, May 14th. ValuEngine cut Ultrapar Participacoes from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 25th.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

See Also: Back-End Load

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.